OmicSyn projects involve participation from hematologists of 12 major Korean university hospitals and approximately 10 information and bio-technology
companies. We are developing real world data and evidence (RWD & RWE) databases and patient reported outcome (PRO) App. related to pediatric
leukemia, CML, MPN, Multiple Myeloma, Non-Hodgkin’s Lymphoma and MDS.
OmicSyn’s hematology platform (HRcds platform) consists of doctor’s App (HDnote), patient’s App (HPnote), and real world data eHR (HRcds).
We are also developing an artificial intelligence analysis platform that combines more than 5000 NGS data with clinical information. Our developing focus
supports hematologists and basic scientists for the development of new diagnostic and therapeutic technologies including novel compounds, novel digital
PCR such as fluidic based- and droplet based-technologies, as well as creating Asian NGS diagnostic panels for early prediction and
diagnosis of hematologic malignancies.
Our company has been supported by the Korean government’s development project and the project was
scheduled to begin in April 2024 and is continuing by the end of 2028. OmicSyn is also looking for further collaborative developing partners
who have interests using our information and real world data collection platforms.